cardamonin and Sjogren-s-Syndrome

cardamonin has been researched along with Sjogren-s-Syndrome* in 1 studies

Trials

1 trial(s) available for cardamonin and Sjogren-s-Syndrome

Article	Year
Cardamonin inhibits pro-inflammatory cytokine production and suppresses NO pathway in PBMCs from patients with primary Sjögren's syndrome. Immunopharmacology and immunotoxicology, 2018, Volume: 40, Issue:2 Primary Sjögren's syndrome (pSS) is a systemic autoimmune disorder with a complex pathophysiology primarily affecting exocrine glands, leading to compromised secretory function. Recent studies imply that many inflammatory mediators, such as pro-inflammatory cytokines and nitric oxide, are critical in the development and perpetuation of pSS systemic manifestations. In the current study, we aimed to investigate the ex vivo immunomodulatory effect of cardamonin (C Topics: Adult; Chalcones; Female; Humans; Inflammation; Interleukin-6; Leukocytes, Mononuclear; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type II; Sjogren's Syndrome; Tumor Necrosis Factor-alpha	2018

Article

Year

Cardamonin inhibits pro-inflammatory cytokine production and suppresses NO pathway in PBMCs from patients with primary Sjögren's syndrome.

Immunopharmacology and immunotoxicology, 2018, Volume: 40, Issue:2

Primary Sjögren's syndrome (pSS) is a systemic autoimmune disorder with a complex pathophysiology primarily affecting exocrine glands, leading to compromised secretory function. Recent studies imply that many inflammatory mediators, such as pro-inflammatory cytokines and nitric oxide, are critical in the development and perpetuation of pSS systemic manifestations. In the current study, we aimed to investigate the ex vivo immunomodulatory effect of cardamonin (C

Topics: Adult; Chalcones; Female; Humans; Inflammation; Interleukin-6; Leukocytes, Mononuclear; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type II; Sjogren's Syndrome; Tumor Necrosis Factor-alpha

2018